Product logins

Find logins to all Clarivate products below.


Atopic dermatitis (AD), also known as (atopic) eczema, is a chronic, relapsing inflammatory skin disease marked by severe pruritus and skin irritation which can have a strong negative impact on patients’ quality of life, in particular in moderate and severe patients. Standard treatments for AD attempt to reduce inflammation and pruritus with combinations of emollients, topical corticosteroids, and topical immunomodulators. Additionally, systemic immunomodulators, and in some cases UV phototherapy, are used to treat AD. Treatment with topical therapies and anti-inflammatory agents is often successful; however, more-effective therapies for treatment-refractory AD represent an area of tremendous unmet need.

Related Market Assessment Reports

Report
Age-Related Macular Degeneration | Pharmacor | G7 | 2015
Last Updated 30 December 2015 In late age-related macular degeneration (AMD), vision deficits are noticeable, often debilitating, and can be a precursor to blindness. The availability of vascular…
Report
Acute Lymphoblastic Leukemia | Niche and Rare Pharmacor | G7 | 2015
Acute lymphoblastic leukemia (ALL), also known as acute lymphoid leukemia or cancer of the white blood cells, develops from lymphocytes overproduced in the bone marrow that spread to other sites…
Report
Hepatitis C Virus (Emerging Market Special Report) | Emerging Markets | China | 2015
Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma in China. The prevalence of this chronic disease remains high owing to the presence of a large…
Report
Methicillin-Resistant Staphylococcus Aureus | Pharmacor | G7 | 2015
Last Updated 29 December 2015 Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The recent…
Report
Hospital-Treated Gram-Negative Infections | Pharmacor | G7 | 2015
Last Updated 23 December 2015 Gram-negative infections (GNIs) account for a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market…